MOTS-c Dosage Guide

Evidence-based protocols for the mitochondrial-derived peptide — AMPK activation, insulin sensitivity, metabolic optimization, exercise mimetic research, and longevity applications.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

MOTS-c

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid mitochondria-derived peptide (MDP) discovered in 2015 by Dr. Changhan David Lee and colleagues at the University of Southern California. It is one of the first mitochondria-derived signaling peptides ever identified — encoded within the mitochondrial genome's 12S rRNA gene, not the nuclear genome.

What makes MOTS-c fundamentally different from virtually every other research peptide is its origin and mechanism. Most peptides are encoded by nuclear DNA and act on cell surface receptors. MOTS-c is encoded by mitochondrial DNA and acts as a retrograde signaling molecule — communicating from the mitochondria back to the nucleus to regulate gene expression. Under metabolic stress, MOTS-c physically translocates from the cytoplasm to the nucleus, where it directly influences adaptive gene expression programs.

The primary target of MOTS-c is AMPK (AMP-activated protein kinase), the master metabolic energy sensor. AMPK activation is the same pathway triggered by exercise, caloric restriction, and metformin. This is why MOTS-c has been described in the research literature as an “exercise mimetic” — it activates many of the same metabolic pathways that physical activity does. In landmark animal studies, MOTS-c prevented age-related insulin resistance and obesity even on high-fat diets.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from animal studies, early human research, and community protocols — not from approved pharmaceutical labeling.

Key Characteristics:

Mitochondria-derived peptide (MDP) — encoded in the mitochondrial genome (12S rRNA gene) — one of the first MDPs ever identified. Not encoded by nuclear DNA.
16-amino-acid peptide — sequence: MRWQEMGYIFYPRKLR. Small peptide with potent intracellular signaling activity.
AMPK activator — activates AMP-activated protein kinase, the master metabolic energy sensor. Same pathway as exercise and metformin.
Retrograde signaling — MOTS-c translocates from cytoplasm to nucleus under metabolic stress, directly regulating adaptive gene expression.
Exercise mimetic properties — activates overlapping metabolic pathways with exercise — enhanced glucose metabolism, fatty acid oxidation, and insulin sensitivity.
Age-related decline — endogenous circulating MOTS-c levels decline with age, correlating with metabolic dysfunction and insulin resistance.

For a complete overview of its mechanism and research, see our full MOTS-c profile. New to peptides? Start with the Beginner's Guide to Peptides.

How MOTS-c Dosage Is Determined

MOTS-c dosing is less established than many other research peptides because it is a relatively recent discovery (2015). The commonly used 5–10 mg daily range is derived primarily from animal study dose extrapolation, early human research, and the growing body of community experience. Large-scale human dose-finding trials have not yet been published.

Landmark Animal Studies (Lee et al., 2015)

The foundational MOTS-c research by Dr. Changhan David Lee's group at USC demonstrated that MOTS-c administration in mice prevented age-dependent insulin resistance, reversed diet-induced obesity on high-fat diets, and improved metabolic homeostasis. These studies used intraperitoneal injection in mice at doses that, when allometrically scaled to human equivalent doses, correspond roughly to the 5–10 mg daily range used in community protocols. The scaling is approximate and standard caveats about mouse-to-human translation apply.

Mechanism-Based Rationale

MOTS-c's primary target is AMPK activation. The dose range is set to achieve meaningful AMPK pathway engagement based on the peptide's observed effects on glucose metabolism, insulin sensitivity, and fatty acid oxidation. Since MOTS-c acts intracellularly through retrograde signaling (not through a traditional cell surface receptor with well-defined binding kinetics), dose-response relationships are more challenging to characterize precisely. The current dosing approach is empirical, informed by metabolic biomarker responses (fasting glucose, insulin sensitivity, energy levels) observed in community use.

Early Human Research

Human clinical trials investigating MOTS-c are underway at several institutions, including studies on exercise capacity and metabolic function. Published results are still limited. The early data is consistent with the metabolic benefits observed in animal models. As more human data becomes available, dosing recommendations may be refined. For now, the 5–10 mg daily subcutaneous range represents the best available evidence from translational research and community experience.

Strength of evidence: Emerging. MOTS-c has strong foundational animal data and a compelling mechanism of action (AMPK activation via mitochondrial retrograde signaling). However, large-scale human clinical trials are still underway with limited published results. The current dosing protocols are based on allometric scaling from animal studies and community experience. This is a very promising peptide at an early stage of clinical validation.

Standard MOTS-c Dosage Ranges

MOTS-c is administered by subcutaneous injection. Unlike many peptides that are dosed in micrograms, MOTS-c is dosed in milligrams — typically 5–10 mg per injection. Loading phases are not typically required. Daily dosing is the standard protocol, though some users dose 3–5 times per week at the higher end of the range.

Dosage by Experience Level

Level	Dose per Injection	Frequency	Weekly Total	Notes
Beginner	5 mg	3x per week	15 mg	Assess tolerance and metabolic response; lower cost entry point
Intermediate	5 mg	Daily (7x/week)	35 mg	Standard active protocol; most common community dosing
Advanced	10 mg	Daily or 5x/week	50–70 mg	Higher dose for targeted metabolic goals; assess whether 5 mg is insufficient before escalating

Injection Timing

Morning administration preferred: Most community protocols recommend morning injection to align with the body's natural metabolic rhythm and AMPK-mediated energy utilization throughout the day
Fasting not strictly required: Unlike GHRPs where food blunts GH release, MOTS-c works through intracellular AMPK activation. However, many users prefer morning fasted injection for consistency
Pre-exercise timing: Some users inject 30–60 minutes before training to potentially enhance exercise-mediated AMPK activation
Consistency matters: Choose a time that you can maintain daily and stick with it throughout the cycle

Milligrams, not micrograms: MOTS-c is dosed in milligrams (mg), not micrograms (mcg). A standard dose is 5 mg — that is 5,000 mcg. This is significantly higher by mass than peptides like BPC-157 (250 mcg) or Ipamorelin (200 mcg). Double-check your units when calculating doses to avoid significant under- or overdosing.

AMPK Activation & Metabolic Pathway

Understanding how MOTS-c works is essential for setting realistic expectations and designing effective protocols. MOTS-c operates through a unique intracellular signaling cascade that is distinct from most research peptides, which typically act on cell surface receptors.

The AMPK Signaling Cascade

AMPK (AMP-activated protein kinase) is the master cellular energy sensor. It is activated when the cell's energy status is low (high AMP:ATP ratio) — triggered naturally by exercise, fasting, and caloric restriction. When AMPK is activated, it shifts the cell from anabolic (building/storing) to catabolic (breaking down/utilizing) mode. MOTS-c activates AMPK through its effects on the folate cycle and de novo purine biosynthesis, triggering a downstream cascade of metabolic effects.

AMPK-Mediated Effect	Mechanism	Practical Outcome
Enhanced glucose uptake	AMPK promotes GLUT4 transporter translocation to cell membranes	Improved glucose disposal; lower fasting blood glucose
Improved insulin sensitivity	AMPK enhances insulin signaling pathways and reduces insulin resistance	Better blood sugar control; reduced fasting insulin levels
Fatty acid oxidation	AMPK inhibits ACC (acetyl-CoA carboxylase), promoting fat burning over fat storage	Increased fat utilization for energy; improved body composition
Mitochondrial biogenesis	AMPK activates PGC-1α signaling, promoting new mitochondria formation	More cellular energy production capacity; improved endurance
Cellular stress response	MOTS-c nuclear translocation activates adaptive stress response genes	Enhanced cellular resilience; improved stress adaptation
Folate cycle regulation	MOTS-c directly modulates the folate cycle and purine metabolism	Upstream metabolic pathway optimization; supports AMPK activation

MOTS-c vs. Other AMPK Activators

Exercise, metformin, and MOTS-c all activate AMPK, but through different upstream mechanisms. Exercise activates AMPK through energy depletion (increased AMP:ATP ratio). Metformin inhibits mitochondrial complex I, indirectly raising AMP levels. MOTS-c modulates the folate cycle and de novo purine biosynthesis, representing a distinct pharmacological approach. In animal studies, MOTS-c improved exercise performance itself — suggesting it may complement and enhance the AMPK activation from physical activity rather than simply replicating it.

Key insight: MOTS-c is not just another metabolic supplement. It represents a fundamentally new class of signaling molecule — a mitochondria-to- nucleus retrograde signal that evolved as part of the mitochondrial genome's communication system. Understanding this mechanism helps explain why MOTS-c's effects are systemic and multifaceted rather than targeted to a single pathway.

Calculate Your MOTS-c Dose

MOTS-c is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 10 mg (10,000 mcg) of MOTS-c
Bacteriostatic water added: 2 mL
Concentration: 10,000 mcg ÷ 2 mL = 5,000 mcg per mL (5 mg/mL)
Target dose: 5 mg (5,000 mcg)
Volume to draw: 5,000 ÷ 5,000 = 1.0 mL = 100 units on an insulin syringe (full syringe)

Quick Reference — 10 mg Vial

Bac Water Added	Concentration	5 mg Dose	10 mg Dose
1 mL	10 mg/mL	50 units (0.5 mL)	100 units (1.0 mL)
2 mL	5 mg/mL	100 units (1.0 mL)	Full vial (2 injections)

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	5 mg Dose
0.5 mL	10 mg/mL	50 units (0.5 mL) — full vial in one dose
1 mL	5 mg/mL	100 units (1.0 mL) — full vial in one dose

Practical note: Because MOTS-c is dosed in milligrams (not micrograms), a 5 mg vial provides only one 5 mg dose. Users on daily protocols will go through vials quickly. Many users purchase 10 mg vials and reconstitute with 1 mL of bacteriostatic water to get two 5 mg doses per vial (50 units each).

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

MOTS-c Dosage by Goal

MOTS-c's broad AMPK-mediated effects make it relevant to multiple health goals. The optimal protocol varies depending on whether you are primarily targeting metabolic optimization, fat loss, exercise performance, or longevity.

Metabolic Optimization & Insulin Sensitivity

The primary application supported by the strongest research evidence. For users targeting improved glucose metabolism, insulin sensitivity, and overall metabolic health markers. This is where MOTS-c's AMPK activation mechanism is most directly relevant. Ideal for individuals with metabolic syndrome risk factors, prediabetic markers, or age-related metabolic decline.

Dose: 5 mg per injection (SubQ)
Frequency: Daily (7x/week)
Cycle: 8 weeks on, 4 weeks off (or continuous at practitioner discretion)
Monitoring: Fasting glucose, fasting insulin, HbA1c, HOMA-IR at baseline and 4–8 weeks

Fat Loss & Body Composition

MOTS-c promotes fat loss through AMPK-mediated fatty acid oxidation, improved glucose disposal (reduced lipogenesis), and enhanced insulin sensitivity. In animal models, MOTS-c prevented diet-induced obesity even on high-fat diets. For fat loss, combining with exercise and caloric management amplifies the metabolic shift toward fat utilization.

Dose: 5–10 mg per injection (SubQ)
Frequency: Daily or 5x/week
Cycle: 6–8 weeks on, 4 weeks off
Stack consideration: 5-Amino-1MQ for metabolic synergy, or AOD-9604 for complementary fat mobilization
Note: Best results when combined with regular exercise and a caloric deficit or maintenance diet. MOTS-c enhances the metabolic environment — it does not override poor dietary habits

Exercise Performance & Endurance

MOTS-c's exercise mimetic properties and its effects on mitochondrial biogenesis (via AMPK → PGC-1α) make it relevant for exercise performance. In animal studies, MOTS-c improved exercise endurance and capacity. Timing injection before training may enhance exercise-induced AMPK activation synergistically.

Dose: 5 mg per injection (SubQ)
Frequency: Daily, or on training days (3–5x/week)
Timing: 30–60 minutes pre-exercise for potential synergistic AMPK activation
Cycle: 4–8 weeks on, 4 weeks off
Note: MOTS-c may complement endurance training more than strength training, given AMPK's role in oxidative metabolism. However, improved glucose metabolism benefits all training modalities

Longevity & Anti-Aging

Endogenous MOTS-c levels decline with age, correlating with metabolic dysfunction. Exogenous MOTS-c aims to restore this mitochondrial signaling molecule to more youthful levels. The longevity application focuses on maintaining metabolic flexibility, insulin sensitivity, mitochondrial function, and cellular stress resilience over time. Conservative, sustainable dosing is appropriate.

Dose: 5 mg per injection (SubQ)
Frequency: 3–5x per week (lower frequency, long-term approach)
Cycle: 8 weeks on, 4 weeks off, repeated. Some longevity practitioners use continuous low-frequency dosing
Monitoring: Metabolic panels, fasting insulin, inflammatory markers (hs-CRP), body composition over time
Note: Longevity applications require consistent, long-term use rather than short intense bursts. Pair with exercise, sleep optimization, and nutritional quality for best outcomes

All goals benefit from exercise. MOTS-c activates AMPK — the same pathway triggered by exercise. Using MOTS-c alongside a regular exercise program provides synergistic AMPK activation that exceeds either approach alone. Do not rely on MOTS-c as a substitute for physical activity.

Cycling Protocols

Unlike GHRPs (such as Hexarelin) where desensitization is well-documented and cycling is mandatory, MOTS-c cycling is precautionary. There is no published evidence of receptor desensitization specific to MOTS-c — it works through intracellular AMPK activation, not a traditional cell surface receptor. Cycling is recommended based on general peptide cycling principles, cost management, and to allow periodic assessment of baseline metabolic function without exogenous support.

Recommended Cycling Protocols

Protocol	On-Cycle	Off-Cycle	Best For
Standard	4–8 weeks daily	4 weeks off	Most users; allows metabolic assessment between cycles
Extended	8–12 weeks daily	4–6 weeks off	Users seeking maximum metabolic adaptation; longer exposure period
Maintenance	Continuous, 3x/week	No formal off-cycle	Long-term longevity protocols; lower frequency reduces cost and allows ongoing assessment
Training-Aligned	Training days only (3–5x/week)	Rest days off	Exercise performance focus; aligns with AMPK activation timing

Why Cycling Is Still Recommended

Baseline assessment: Off-cycle periods allow you to evaluate your natural metabolic function without exogenous support. This helps determine whether MOTS-c is producing meaningful improvements that persist.
Cost management: At 5–10 mg daily, MOTS-c consumption adds up quickly. Cycling reduces overall cost while maintaining the bulk of metabolic benefits.
Precautionary principle: Long-term continuous MOTS-c administration has not been studied in humans. Periodic breaks are a reasonable precaution when long-term safety data is absent.
Preventing metabolic dependency: Maintaining natural metabolic function through diet, exercise, and lifestyle is the foundation. MOTS-c should augment these habits, not replace them.

Off-cycle strategy: During off-cycle periods, maintain exercise, nutrition, and sleep habits that support metabolic health. The metabolic improvements initiated by MOTS-c (improved insulin sensitivity, enhanced mitochondrial function) may persist to some degree after discontinuation, especially if supported by consistent lifestyle factors.

MOTS-c Stacking Protocols

MOTS-c's AMPK-mediated mechanism of action makes it compatible with a range of metabolic, weight management, and longevity peptides. The key stacking principle is to combine compounds that work through complementary pathways rather than redundant ones.

MOTS-c + 5-Amino-1MQ — Metabolic Synergy Stack

The most compelling metabolic stack. MOTS-c activates AMPK (promoting catabolic metabolism), while 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme linked to obesity and metabolic dysfunction. These two compounds work through entirely different mechanisms to converge on improved metabolic function, fat metabolism, and energy utilization.

Compound	Dose	Frequency	Purpose
MOTS-c	5 mg SubQ	Daily	AMPK activation; glucose metabolism; fatty acid oxidation
5-Amino-1MQ	50–100 mg oral	Daily	NNMT inhibition; NAD+ metabolism; fat cell differentiation reduction

MOTS-c + GLP-1 Agonist — Weight Management Stack

Combines MOTS-c's metabolic optimization with the appetite-suppressing and glucose-regulating effects of GLP-1 receptor agonists like Tirzepatide or Semaglutide. The GLP-1 agonist addresses appetite and caloric intake, while MOTS-c optimizes how the body processes and utilizes the energy it receives. Complementary mechanisms targeting different aspects of the weight management equation.

Compound	Dose	Frequency	Purpose
MOTS-c	5 mg SubQ	Daily	Metabolic optimization; AMPK activation; insulin sensitivity
Tirzepatide or Semaglutide	Per titration protocol	Weekly	Appetite regulation; GLP-1 mediated glucose control; weight reduction

Dosing note: GLP-1 agonists like Tirzepatide and Semaglutide have their own specific titration schedules. See the individual dosage guides for those compounds. MOTS-c dosing does not change when stacked with GLP-1 agonists.

MOTS-c + AOD-9604 — Fat Loss Stack

Pairs MOTS-c's AMPK-mediated metabolic optimization with AOD-9604's targeted fat mobilization mechanism. AOD-9604 is a modified fragment of human growth hormone that stimulates lipolysis (fat breakdown) without the growth-promoting effects of full-length HGH. MOTS-c improves the metabolic processing of mobilized fatty acids through enhanced oxidation.

Compound	Dose	Frequency	Purpose
MOTS-c	5 mg SubQ	Daily	AMPK activation; fatty acid oxidation; metabolic optimization
AOD-9604	300 mcg SubQ	Daily (fasted, morning)	Lipolysis stimulation; fat mobilization without GH-related growth effects

MOTS-c + Tesamorelin — Metabolic & Body Composition Stack

Combines MOTS-c's AMPK pathway with Tesamorelin's GHRH-mediated GH release. Tesamorelin is particularly effective for visceral adipose tissue (VAT) reduction and is one of the few peptides with FDA approval (for HIV-associated lipodystrophy). Together, they address metabolism from two angles: MOTS-c optimizes cellular energy utilization while Tesamorelin's GH elevation promotes lipolysis and body composition improvement.

Compound	Dose	Frequency	Purpose
MOTS-c	5 mg SubQ	Daily	AMPK activation; insulin sensitivity; fatty acid oxidation
Tesamorelin	1–2 mg SubQ	Daily (before bed, fasted)	GHRH-mediated GH release; visceral fat reduction; body composition

Introduce compounds one at a time. When building a stack, add MOTS-c first and establish your baseline response over 2–4 weeks before adding a second compound. This allows you to attribute changes to specific compounds and identify any adverse reactions. Stacking multiple new compounds simultaneously makes it impossible to determine what is working and what is causing side effects.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: MOTS-c has limited published human safety data. Animal studies have shown a favorable safety profile at relevant doses. Community reports suggest it is generally well-tolerated with mild, manageable side effects. However, long-term human safety has not been established through clinical trials. Use with appropriate caution and medical supervision.

Reported Side Effects

Generally mild and self-limiting:

Injection site reactions — redness, minor swelling, or soreness at the injection site. The most commonly reported side effect. Rotate injection sites to minimize.
Gastrointestinal discomfort — occasional nausea, mild GI upset, or changes in digestion. Usually transient and resolves within the first week of use.
Headache — rare, typically mild, and most commonly reported during the first few days of use. Usually resolves with continued administration.
Fatigue or lethargy — uncommon. May reflect metabolic shifting in the initial adaptation period. Should resolve within 1–2 weeks.

Theoretical concerns (not widely reported but worth monitoring):

Blood glucose changes — MOTS-c directly affects glucose metabolism. Users with diabetes or on glucose-lowering medications should monitor blood glucose carefully to avoid hypoglycemia.
Metabolic adaptation — long-term continuous AMPK activation could theoretically interfere with anabolic processes. This is a theoretical concern primarily relevant to those seeking muscle hypertrophy alongside MOTS-c use.

Side effect profile is notably mild compared to many other research peptides. MOTS-c does not elevate cortisol, prolactin, or appetite (unlike GHRPs). It does not cause water retention, numbness, or hormonal disruption. The most common issues are injection site reactions and transient GI discomfort. Most users tolerate MOTS-c well.

Contraindications

Active cancer or history of cancer — while AMPK activation is generally considered tumor-suppressive in many contexts, the effects of exogenous MOTS-c on cancer biology are not fully characterized. Avoid use with active malignancies until more data is available.
Pregnancy and breastfeeding — no safety data exists for MOTS-c during pregnancy or nursing. Avoid entirely.
Type 1 diabetes or insulin-dependent diabetes — MOTS-c directly affects glucose metabolism and insulin sensitivity. Use in diabetic patients requires close medical supervision and blood glucose monitoring to prevent hypoglycemia.
Concurrent use of glucose-lowering medications — metformin, sulfonylureas, insulin, or SGLT2 inhibitors combined with MOTS-c could produce additive glucose-lowering effects. Medical supervision is essential to prevent hypoglycemia.
Severe hepatic or renal impairment — no pharmacokinetic data exists for MOTS-c in patients with organ dysfunction. Avoid use without medical guidance.

Recommended Monitoring

Because MOTS-c directly affects metabolic pathways, objective monitoring is more important — and more feasible — than with many other research peptides. The following blood work provides clear before-and-after metrics:

Fasting glucose — primary metabolic endpoint. Expect improvement if elevated at baseline.
Fasting insulin — measures insulin resistance directly. Improved insulin sensitivity should lower fasting insulin levels.
HbA1c — 3-month average blood glucose. Best measured before starting and after 8–12 weeks of use.
HOMA-IR — calculated from fasting glucose and fasting insulin. The most sensitive metric for insulin resistance changes.
Lipid panel — total cholesterol, LDL, HDL, triglycerides. AMPK activation may improve lipid profiles.
Body composition — DEXA scan or consistent measurement protocol. Tracks fat mass and lean mass changes over time.

Regulatory Status: MOTS-c is not FDA-approved for any human use. It is classified as a research peptide / research chemical. Human clinical trials are underway but limited published results are available. Regulations vary by jurisdiction — verify your local laws before purchasing. MOTS-c has not been specifically listed by WADA but athletes should verify current prohibited substance lists before use.

Common MOTS-c Dosing Mistakes

Avoid these common errors to get the most out of your MOTS-c protocol:

Treating MOTS-c as a fat burner instead of a metabolic optimizer: MOTS-c is not a direct fat-burning agent like a thermogenic or lipolytic compound. It works by optimizing metabolic pathways through AMPK activation — improving insulin sensitivity, glucose metabolism, and fatty acid oxidation. Results come from improved metabolic function over time, not acute fat loss. Set expectations accordingly and combine with proper diet and exercise.

Using oral administration instead of subcutaneous injection: MOTS-c is a 16-amino-acid peptide that is completely degraded by gastrointestinal enzymes. Oral administration provides zero bioavailability. It must be injected subcutaneously. Any vendor selling “oral MOTS-c” is selling an ineffective product.

Expecting immediate results within the first few days: MOTS-c works through gene expression regulation and metabolic pathway optimization. These are not overnight processes. Most users report noticeable effects (improved energy, exercise performance, metabolic markers) at 2–4 weeks. Body composition changes typically require 4–8 weeks of consistent use. Be patient and assess results at the end of a full cycle.

Not combining with exercise and proper nutrition: While MOTS-c has been called an exercise mimetic, it works best in combination with actual physical activity and sound nutrition. MOTS-c enhances the metabolic pathways that exercise activates — using it without exercise is missing the synergistic benefit. Think of MOTS-c as an amplifier, not a replacement.

Storing reconstituted MOTS-c at room temperature: Like all reconstituted peptides, MOTS-c must be stored refrigerated (2–8°C / 36–46°F) after reconstitution with bacteriostatic water. Room temperature storage accelerates degradation. Lyophilized (unreconstituted) MOTS-c can be stored frozen for longer shelf life. Once reconstituted, use within 3–4 weeks.

Using excessively high doses beyond 10 mg daily: Community protocols rarely exceed 10 mg daily, and there is no evidence that higher doses produce proportionally greater benefits. Higher doses increase cost significantly without established additional benefit. Start at 5 mg and only increase to 10 mg if needed. More is not better with MOTS-c.

Neglecting metabolic blood work before and during use: MOTS-c directly affects glucose metabolism and insulin sensitivity. Baseline and follow-up blood work — including fasting glucose, fasting insulin, HbA1c, and a lipid panel — is the most objective way to assess whether MOTS-c is producing meaningful metabolic improvements. Without blood work, you are guessing about efficacy.

Stacking too many metabolic compounds simultaneously: Adding MOTS-c to a stack with multiple other metabolic agents (e.g., Tirzepatide + 5-Amino-1MQ + MOTS-c + AOD-9604 simultaneously) makes it impossible to determine what is working and increases the risk of unexpected interactions. Introduce MOTS-c as a single variable, assess its effects, then consider adding complementary compounds one at a time.

Ignoring injection site rotation: Subcutaneous injections should be rotated between sites (abdomen, thigh, upper arm) to prevent lipodystrophy, scar tissue buildup, and localized reactions. Injecting in the same spot repeatedly reduces absorption consistency and can cause persistent injection site issues.

Frequently Asked Questions

Key Takeaways

MOTS-c is a mitochondria-derived peptide (MDP) — encoded in the mitochondrial genome, not nuclear DNA. It acts as a retrograde signaling molecule between mitochondria and nucleus.
Standard dose: 5–10 mg SubQ daily or 3–5x/week — dosed in milligrams, not micrograms. Most protocols use 5 mg daily as the baseline.
Primary mechanism: AMPK activation — the master metabolic energy sensor. Same pathway activated by exercise, fasting, and metformin.
Metabolic effects: enhanced glucose metabolism, improved insulin sensitivity, promoted fatty acid oxidation, mitochondrial biogenesis, and cellular stress response regulation.
Exercise mimetic properties — activates overlapping metabolic pathways with exercise but is not a replacement for physical activity. Best results when combined with regular exercise.
Endogenous levels decline with age — correlating with age-related metabolic dysfunction and insulin resistance. Exogenous administration aims to restore mitochondrial signaling.
Best stacks: 5-Amino-1MQ (metabolic synergy), Tirzepatide/Semaglutide (weight management), AOD-9604 (fat loss).
Cycling: 4–8 weeks on, 4 weeks off is standard. Cycling is precautionary, not driven by documented desensitization.
Side effects are mild — injection site reactions, occasional GI discomfort, rare headache. No cortisol, prolactin, or hormonal disruption.
Monitor metabolic blood work — fasting glucose, fasting insulin, HbA1c, and HOMA-IR provide objective assessment of MOTS-c's effects.
Not FDA-approved — classified as a research peptide. Evidence strength is emerging but promising. Human clinical trials are underway with limited published results.

This article is for educational and informational purposes only. See our Disclaimer.

References

Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab. 2015;21(3):443-454. PubMed
Lee C, Kim KH, Cohen P. “MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.” Free Radic Biol Med. 2016;100:182-187. PubMed
Kim KH, Son JM, Benayoun BA, Lee C. “The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.” Cell Metab. 2018;28(3):516-524.e7. PubMed
Reynolds JC, Lai RW, Woodhead JST, et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nat Commun. 2021;12(1):470. PubMed
Zhai D, Ye Z, Jiang Y, et al. “MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA.” Mol Immunol. 2017;92:151-160. PubMed
Ming W, Lu G, Xin S, et al. “Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation.” Biochem Biophys Res Commun. 2016;476(4):412-419. PubMed
Yin X, Jing Y, Chen Q, et al. “The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.” Pharmacol Res. 2022;175:105987. PubMed
D'Souza RF, Woodhead JST, Hedges CP, et al. “Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition.” Aging (Albany NY). 2020;12(6):5244-5258. PubMed
Kumagai H, Coelho AR, Wan J, et al. “MOTS-c reduces myostatin and muscle atrophy signaling.” Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. PubMed

Next Steps

Continue your research with these resources.

5-Amino-1MQ Dosage Guide

Learn dosing protocols for 5-Amino-1MQ — the NNMT inhibitor that pairs synergistically with MOTS-c for metabolic optimization.

Read Guide

Dosage Calculator

Calculate your exact MOTS-c dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory